Publicaciones científicas
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3
Salcedo M (1), Prieto M (2), Castells L (3), Pascasio JM (4), Montero Alvarez JL (5), Fernández I (6), Sánchez-Antolín G (7), González-Diéguez L (8), García-Gonzalez M (9), Otero A (10), Lorente S (11), Espinosa MD (12), Testillano M (13), González A (14), Castellote J (15), Casafont F (16), Londoño MC (17), Pons JA (18), Molina Pérez (19), Cuervas-Mons V (20), Pascual S (21), Herrero JI (22), Narváez I (23), Vinaixa C (24), Llaneras J (25), Sousa JM (26), Bañares R (27).
RESUMEN
Direct-acting antiviral agents (DAA) combining daclatasvir (DCV) have reported good outcomes in the recurrence of hepatitis C virus (HCV) infection after liver transplant (LT).
However, its effect on the severe recurrence and the risk of death remains controversial. We evaluated the efficacy, predictors of survival, and safety of DAC-based regimens in a large real-world cohort. A total of 331 patients received DCV-based therapy.
Duration of therapy and ribavirin use were at the investigator's discretion. The primary end point was sustained virological response (SVR) at week 12. A multivariate analysis of predictive factors of mortality was performed.
Intention-to-treat (ITT) and per-protocol SVR were 93.05% and 96.9%. ITT-SVR was lower in cirrhosis (n = 163) (96.4% vs. 89.6% P = 0.017); the SVR in genotype 3 (n = 91) was similar, even in advanced fibrosis (96.7% vs. 88%, P = 0.2). Ten patients (3%) experienced virological failure. Therapy was stopped in 18 patients (5.44%), and ten died during treatment.
A total of 22 patients (6.6%) died. Albumin (HR = 0.376; 95% CI 0.155-0.910) and baseline MELD (HR = 1.137; 95% CI: 1.061-1.218) were predictors of death. DCV-based DAA treatment is efficacious and safe in patients with HCV infection after LT.
Baseline MELD score and serum albumin are predictors of survival irrespective of viral response.
CITA DEL ARTÍCULO Transpl Int. 2017 Jun 13. doi: 10.1111/tri.12999
Nuestros autores
